美托洛尔联合厄贝沙坦治疗慢性充血性心衰80例临床研究被引量：15

下载PDF

导出

摘要观察美托洛尔联合厄贝沙坦治疗慢性充血性心衰的治疗效果。80例慢性充血性心衰患者随机分为A组和B组,两组均给予常规治疗,A组在常规治疗的基础上加用心律平治疗,B组在常规治疗的基础上加用美托洛尔+厄贝沙坦治疗。评价两组患者治疗前后心功能改善情况,观察两组治疗前后生命体征改善情况。两组治疗后LVEF、NYHA评分显著优于治疗前,B组改善效果更显著(P<0.05)。两组治疗后HR、SBP、DBP显著优于治疗前,B组改善效果更显著(P<0.05)。常规治疗+美托洛尔+厄贝沙坦治疗慢性充血性心力衰竭临床效果显著,心功能、心率及血压改善显著,值得临床推广应用。

作者吴静

机构地区榆林市榆阳区人民医院内科

出处《现代诊断与治疗》 CAS 2016年第19期3584-3585,共2页 Modern Diagnosis and Treatment

关键词美托洛尔厄贝沙坦慢性充血性心力衰竭

分类号 R541.61 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1林有为,林楚连.厄贝沙坦联合美托洛尔治疗慢性心力衰竭30例疗效观察[J].中国现代医生,2011,49(7):18-18. 被引量：15
2石敬华,朱开勇.用厄贝沙坦氢氯噻嗪片联合美托洛尔治疗重症心力衰竭的效果解析[J].当代医药论丛,2014,12(18):198-199. 被引量：3
3阿布都沙拉木.阿布都热衣木,省格丽,胡晓灵.酒石酸美托洛尔平片与琥珀酸美托洛尔缓释片对收缩性心衰患者疗效观察[J].新疆医学,2014(6):29-32. 被引量：4
4张权宇,宣风琦,荣晶晶,邓捷,王效增,韩雅玲.琥珀酸美托洛尔与美托洛尔对慢性充血性心衰患者心功能的影响[J].现代生物医学进展,2013,13(32):6285-6288. 被引量：20
5卢迎宏.厄贝沙坦氢氯噻嗪早期联合美托洛尔治疗老年心力衰竭疗效观察[J].中国现代药物应用,2013,7(20):108-109. 被引量：6
6张荣奎,彭晓玲,林泽鹏,张志伟.目标剂量美托洛尔缓释片治疗明显改善原发性高血压伴心衰患者预后[J].现代医院,2012,12(7):13-15. 被引量：15
7赵云泉.厄贝沙坦配合美托洛尔对充血性心衰合并室性心律失常的治疗作用[J].中国现代药物应用,2011,5(23):7-8. 被引量：16

二级参考文献40

1STANEK B, FREY B, HULSMANN M, et al. Prognostic evalua- tion of neurohumoral plasma levels before and during beta - bloc- ker therapy in advance left ventricular dysfunction[ J]. J Am Coil Cardiol,2001,38 :36 -42.
2LI C, CANTOR W J. Arterial repair after stenting and the effccts of GM6001, a matrix metalloproteinase inhibitor[J]. J Am Coll Cardiol, 2002,39( 11 ) :1852 - 1858.
3CHIN S P, CHUNG NAY, GIBBS C R, et al. Vascular endotheli- al growth factor and soluble P-selectin in acute and chronic heart factor [ J ]. Am J Cardiol,2002,90 : 1258 - 1260.
4REINHARD D, SIGUSCH H H, HENSSE J, et al. Cardiac re- modeling in end stage heart failure:upregulition of matrix metallo- proteinase (MMP) irrespective of the underlying diseace,and evi- dence for a direct inhibitory effect of ACE inhibitors on MMP[ J]. Heat, 2002,88:525 - 530.
5Zhao Q, Yu S, Huang H, et al. The seasonal variation in hospitaliza- tions duc to chronic systolic heart failure correlates with blood sodi- um levels and cardiac function [J]. Exp Clin Cardiol, 2013, 18(2): 77-80.
6Whorlow SL, Krum H. Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure [J]. Am J Cardiol, 2000, 86 (8): 886-889.
7McKelvie RS, Moe GW, Ezekowitz JA, et al. The 2012 Canadian Car- diovascular Society heart failure management guidelines update: fo- cus on acute and chronic heart failure [J]. Can J Cardiol, 2013, 29(2): 168-181.
8Hunt SA; American College of Cardiology; American Heart Associa- tion Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) [J]. J Am Coil Cardiol, 2005, 46(6):e1-82.
9Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Or nato JP, Page RL, Riegel B; American College of Cardiology; American Heart Associa- tion Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Di- agnosis and Management of Chronic Heart Failure in the Adult: a re- port of the American College of Cardiology/American Heart Associa- tion Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society [J]. Circula- tion, 2005, 112(12):e154-235.
10Krishnamurthy P, Subramanian V, Singh M, et al. Betal integrins modulate beta-adrenergic receptor-stimulated cardiac myocyte apop- tosis and myocardial remodeling [J]. Hypertension, 2007, 49 (4): 865-872.